Full Name
Ho, H.K.
Ho H.K
Ho, Han Kiat
Ho Han Kiat
Other emails


Results 1-20 of 37 (Search time: 0.011 seconds).

Issue DateTitleAuthor(s)
1Aug-2012An investigation of the bioactivation potential and metabolism profile of zebrafish versus humanChng, H.T.; Ho, H.K. ; Yap, C.W. ; Lam, S.H. ; Chan, E.C.Y. 
219-Feb-2019Angiopoietin-1 accelerates restoration of endothelial cell barrier integrity from nanoparticle-induced leakinessJie Kai Tee ; Magdiel Setyawati ; Fei Peng ; David Leong ; Han Kiat Ho 
31-Feb-2014Asian study of clopidogrel (ASCLOP) responsiveness: The contributions of genetic and non-genetic factorsTan, D.S.Y. ; Yeo, A.H.L.; Ho, H.K. ; Wee, H.L. ; Ong, H.Y.
42006Bioactivation and hepatotoxicity of nitroaromatic drugsBoelsterli, U.A. ; Leow, K.Y.; Zhou, S. ; Ho, H.K. 
5Dec-2013Carbon nanotubes for delivery of small molecule drugsWong, B.S.; Yoong, S.L.; Jagusiak, A.; Panczyk, T.; Ho, H.K. ; Ang, W.H. ; Pastorin, G. 
62015Comparative hepatoprotective effects of tocotrienol analogs against drug-induced liver injuryTan, Cheauyih; Saw, Tzuenyih; Fong, Cheewai; Ho, Han Kiat 
7Jan-2014Current strategies for inhibiting FGFR activities in clinical applications: Opportunities, challenges and toxicological considerationsHo, H.K. ; Yeo, A.H.L.; Kang, T.S. ; Chua, B.T.
85-Dec-2013Cytokines as mediators of chemotherapy-associated cognitive changes: Current evidence, limitations and directions for future researchCheung, Y.T.; Lim, S.R.; Ho, H.K. ; Chan, A. 
9Apr-2013Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testingHo, H.K. ; Németh, G.; Ng, Y.R.; Pang, E.; Szántai-Kis, C.; Zsákai, L.; Breza, N.; Greff, Z.; Horváth, Z.; Pató, J.; Szabadkai, I.; Szokol, B.; Baska, F.; Orfi, L.; Ullrich, A.; Kéri, G.; Chua, B.T.
10Jun-2010Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytesSaha, S.; New, L.S. ; Ho, H.K. ; Chui, W.K. ; Chan, E.C.Y. 
11Jun-2012Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: Clinical and in vitro evidenceTeo, Y.L.; Saetaew, M.; Chanthawong, S.; Yap, Y.S.; Yong Chan, E.C. ; Ho, H.K. ; Chan, A. 
12Jan-2014Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum(IV) prodrug of cisplatinYoong, S.L.; Wong, B.S.; Zhou, Q.L.; Chin, C.F.; Li, J. ; Venkatesan, T. ; Ho, H.K. ; Yu, V.; Ang, W.H. ; Pastorin, G. 
132017Evaluation of plasma brain-derived neurotrophic factor levels and self-perceived cognitive impairment post-chemotherapy: A longitudinal studyNg T.; Lee Y.Y.; Chae J.-W.; Yeo A.H.L. ; Shwe M. ; Gan Y.X.; Ng R.C.H. ; Chu P.P.Y.; Khor C.C. ; Ho H.K. ; Chan A. 
1415-Oct-2013Global gas chromatography/time-of-flight mass spectrometry (GC/TOFMS)-based metabonomic profiling of lyophilized human fecesPhua, L.C.; Koh, P.K.; Cheah, P.Y.; Ho, H.K. ; Chan, E.C.Y. 
152015Hepatotoxic potential of asarones: In vitro evaluation of hepatotoxicity and quantitative determination in herbal productsPatel, D.N ; Ho, H.K ; Tan, L.L; Tan, M.-M.B; Zhang, Q; Low, M.-Y; Chan, C.-L ; Koh, H.-L 
164-Jun-2012Immobilisation of quantum dots by bio-orthogonal PCR amplification and labelling for direct gene detection and quantitationTian, Q. ; Wong, W.; Xu, Y.; Chan, Y. ; Ho, H.K. ; Pastorin, G. ; Ang, W.H. 
172016Impact of TNF-α (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer PatientsChae J.-W.; Ng T.; Yeo H.L.; Shwe M.; Gan Y.X.; HO HAN KIAT ; Chan A. 
182018Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson�s DiseaseBaek J.-S.; Tee J.K. ; Pang Y.Y. ; Tan E.Y.; Lim K.L. ; Ho H.K. ; Loo S.C.J.
19Jul-2012Interaction of lapatinib with cytochrome P450 3A5Chan, E.C.Y. ; New, L.S. ; Chua, T.B.; Yap, C.W. ; Ho, H.K. ; Nelson, S.D.
20Mar-2013Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapyPhua, L.C.; Mal, M.; Koh, P.K.; Cheah, P.Y.; Chan, E.C.Y. ; Ho, H.K.